Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies (NCT02179359) | Clinical Trial Compass
TerminatedNot Applicable
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
Stopped: Replaced by another study
United States38 participantsStarted 2014-09-02
Plain-language summary
This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.
Who can participate
Age range55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of Sickle Cell Disease, Thalassemia, Diamond Blackfan Anemia or other non-malignant hematologic disorders for which a stem cell transplant is indicated
* Acceptable stem cell source identified
* Performance status of ≥ 70% (Karnofsky),or ≥ 70 (Lansky play score)
* Creatinine \<2.0 mg/dl for adults or glomerular filtration rate \> 50 ml/min for children
* Bilirubin, Aspartate Aminotransferase, Alkaline phosphatase \<5 times the upper limit of institutional normal
* Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction \> 40%
Exclusion Criteria:
* active, uncontrolled infection
* pregnant or breastfeeding
* HIV positive
What they're measuring
1
incidence of graft failure
Timeframe: 42 days
Trial details
NCT IDNCT02179359
SponsorMasonic Cancer Center, University of Minnesota